|
|
|
|
| LEADER |
01000naa a22002652c 4500 |
| 001 |
NLM394052315 |
| 003 |
DE-627 |
| 005 |
20251017233323.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
251017s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2025.110609
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1602.xml
|
| 035 |
|
|
|a (DE-627)NLM394052315
|
| 035 |
|
|
|a (NLM)41093046
|
| 035 |
|
|
|a (PII)S1521-6616(25)00184-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ledoult, Emmanuel
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Dual role of plasmablasts as immune regulators or amplifiers in COVID-19
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 16.10.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a ClinicalTrials.gov: NCT04341792, NCT04327180
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a COVID-19 induces a marked plasmablast (PB) expansion, whose functional role remains unclear. We performed B-cell immunophenotyping and multiplex cytokine analysis in a prospective cohort of 50 COVID-19 patients. PB expansion occurred early and correlated with both maximal disease severity and inflammatory markers. A retrospective cohort of 282 steroid-naïve patients was used to validate PB dynamics, model trajectories, and perform transcriptomic profiling. Two PB trajectories emerged: a transient one and a persistent, amplified one, the latter associated with a sixfold increase in 30-day mortality (p < 0.001). In severe cases, PB upregulated purine metabolism genes; in non-severe cases, they expressed interferon and CIITA-mediated MHC-II programs. BAFF levels at day 7 correlated with severity suggesting a role in sustaining PB expansion. PB exhibit functional duality in COVID-19-acting as immune regulators in non-severe cases and as inflammation amplifiers in severe disease. BAFF emerges as a potential therapeutic target in PB-driven immune dysregulation. Trial registration.ClinicalTrials.govNCT04327180 and NCT04341792
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a BAFF
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Plasmablast
|
| 700 |
1 |
|
|a Guerrier, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dubucquoi, Sylvain
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Figeac, Martin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Villenet, Céline
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Daunou, Blanche
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Behal, Helene
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pokeerbux, Mohammad Ryadh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Machet, Thomas
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Koether, Vincent
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Collet, Aurore
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Launay, David
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a Lille Covid Research network (LICORNE)
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 281(2025) vom: 13. Okt., Seite 110609
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:281
|g year:2025
|g day:13
|g month:10
|g pages:110609
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2025.110609
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 281
|j 2025
|b 13
|c 10
|h 110609
|